RapidAI has been named to CB Insights’ fifth-annual Digital Health 50 (formerly Digital Health 150), a list of the 50 most promising private digital health companies of 2023.
The company recently launched its Edge Cloud Platform and received both Shonin (premarket approval) clearance and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rapid SDH detection tool for CT imaging. This came after RapidAI completed a $75 million series C funding round earlier in 2023.
The 2023 Digital Health 50 honorees were selected from a pool of over 10,000 companies. RapidAI was selected within the "Diagnosis & Imaging" category, which honors companies focused on early detection and diagnosis.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
